| SYNDAX PHARMACEU.DL-,0001 |
| USA |
| Gesundheit |
| US87164F1057 / A2AFL6 |
| 1T3 (Frankfurt) / SNDX (NASDAQ) |
| FRA:1T3, ETR:1T3, 1T3:GR, NASDAQ:SNDX |
| - |
| https://www.syndax.com/ |
|
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its current portfolio centers on treatments for hematologic malignancies and serious immune-related co..
>Volltext.. |
| 1354.48 Mio. EUR |
| 1390.87 Mio. EUR |
| 225.2 Mio. EUR |
| -173.34 Mio. EUR |
| -197.09 Mio. EUR |
| -2.25 EUR |
| 526.18 Mio. EUR |
| 300.4 Mio. EUR |
| -196.98 Mio. EUR |
| 5.5 |
| 232.81% |
| 32.02% |
| - |
| - |
| - |
| - |
| SYNDAX |
| 13.10.26 |
|